RxDoctor Payments Data

Jeffrey Weinberger, MD

Vascular Surgery · Indianapolis, INNPI 1164637070

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $15,505 of the $20,146 with a category attached, or 77.0%. 36 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 27.9% of the total.

$20,146in general payments, 2019–2025

Across 360 payments — averaging $55.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$6K
  • Boston Scientific$3K
  • Heraeus Medical Components, LLC$2K
  • Johnson & Johnson$1K
  • Silk Road Medical, Inc.$1K
  • Endologix LLC$1K
  • plus $7K from 30 others

What the payments were for

  • Consulting fees$2,10010%
  • Travel & lodging$2,53113%
  • Food & beverage$15,50577%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,146 in reported general payments places this provider in the 85th percentile of 71 vascular surgery providers in Indiana.

See all vascular surgery providers in Indiana

Medicare billing

Part B allowed, 2024
$200,748
Medicare patients
791
Services billed
1,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban83$82,203
EliquisApixaban58$51,872
ClopidogrelClopidogrel Bisulfate157$1,475
Cilostazol53$1,264
Atorvastatin Calcium101$598
Pentoxifylline13$270
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen43$238
Gabapentin11$218
Mupirocin18$113
Prednisone14$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,281$82,20383 claims
PfizerEliquis$171$51,87258 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 71 vascular surgery providers in Indiana.

Other vascular surgery in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →